Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2440599 | 1.00 | DRD2 (0.35) | DRD2HTR2AHTR7KCNH2ELANE | |
| SCHEMBL12329398 | 0.90 | PYGL (0.35) | DRD2HTR2AHTR7KCNH2ELANE | |
| SCHEMBL2441780 | 0.88 | CMA1 (0.39) | — | |
| SCHEMBL12299562 | 0.88 | CMA1 (0.39) | — | |
| SCHEMBL2622108 | 0.86 | ELANE (0.39) | ELANEF2CTSG | |
| SCHEMBL9611410 | 0.86 | ELANE (0.39) | ELANEF2CTSG | |
| SCHEMBL2622092 | 0.86 | ELANE (0.39) | ELANEF2CTSG | |
| SCHEMBL12299529 | 0.86 | ELANE (0.39) | ELANEF2CTSG | |
| SCHEMBL12299566 | 0.85 | TGM2 (0.33) | DRD2HTR2AHTR7KCNH2 | |
| SCHEMBL2441314 | 0.85 | TGM2 (0.33) | DRD2HTR2AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | DRD2 4857/4885HTR2A 4101/4885HTR7 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.